Levetiracetam in migraine prophylaxis: A randomized placebo-controlled study in a rural medical institute in northern India

Clinical Neuropharmacology

Volumn 36, Issue 6, 2013, Pages 193-197

  Verma, Archana ^a   Srivastava, Dhiraj ^b   Kumar, Alok ^a   Singh, Vineeta ^c  

^a UP Rural Institute of Medical Sciences and Research   (India)

^b Department of SPM ^*  (Iran)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Headache; levetiracetam; migraine prophylaxis

Indexed keywords

AMITRIPTYLINE; ETIRACETAM; FLUNARIZINE; IBUPROFEN; KETOROLAC; NAPROXEN; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN;

ADOLESCENT; ADULT; ARTICLE; ASTHENIA; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; NEUROLOGIC EXAMINATION; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; VOMITING;

ADOLESCENT; ADULT; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PIRACETAM; PROSPECTIVE STUDIES; RURAL HEALTH SERVICES; YOUNG ADULT;

EID: 84888131828     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000005     Document Type: Article

References (23)

1. WHO (2001) The World Health Report 2001: Mental health, new understanding new hope. World Health Organization, Geneva, Switzerland. (http://www. who. int/whr/2001/main/en /overview/outline. htm).
2. D'Amico D. Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability. Neurol Sci 2007;28(2):S188-S197.
3. Welch KMA, D'Andrea G, Tepley N. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 1990;8:817-828.
4. Apostol G, Lewis DW, Laforet GA, et al. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache 2009;49(1):45-53.
5. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-973.
6. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci 2004;101:9861-9866.
7. Klitgaard H, Pitkanen A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord 2003;5(Suppl):S9-S16.
8. Gallai V, Alberti A, Rossi C, et al. An open-label study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine. J Headache Pain 2003;4:92-96.
9. Young W, Shaw J, Bloom M, et al. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam treated subjects. Headache 2008;48:1490-1498.
10. Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache 2004;44:238-243.
11. Rapoport AM, Bigal ME. Migraine preventive therapy: current and emerging treatment options. Neurol Sci 2005;26:S111-S120.
12. Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66:1654-1660.
13. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):24-36.
14. Sample Size Calculator: One Sample Mean. http://www. cct. cuhk. edu. hk/stat/mean/osm-sup. htm#2.
15. Antonaci F, Chimento P, Diener HC, et al. Lessons from placebo effects in migraine treatment. J Headache Pain 2007;8:63-66.
16. Diener HC, Schorn CF, Bingel U, et al. Importance of placebo in headache research. Cephalalgia 2008;28:1003-1011.
17. Cochran JW. Levetiracetam as migraine prophylaxis. Clin J Pain 2004;20:198-199.
18. Pakalnis A, Kring D, Meier L. Levetiracetam prophylaxis in pediatric migraine-an open-label study. Headache 2007;47:427-430.
19. Krusz JC. Levetiracetam as prophylaxis for resistant headaches. Cephalalgia 2001;21:373 (Abstract).
20. Brighina F, Palermo A, Aloisio A, et al. Levetiracetam in the prophylaxis of migraine with aura: a 6 month open-label study. Clin Neuropharmacol 2006;29:338-342.
21. Pizza V, Busillo V, Agresta A, et al. Elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam. Cent Nerv Syst Agents Med Chem 2011;11(1):31-34.
22. Rapoport AM, Sheftell FD, Tepper SJ, et al. Levetiracetam in the preventive treatment of transformed migraine: a prospective, open-label, pilot study. Curr Ther Res 2005;66(3):212-221.
23. Beran RG, Spira PJ. Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study (The Australian KEPPRA Headache Trial [AUS-KHT]). Cephalalgia 2011;31:530-536.